Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer

Natural killer (NK) cells are attractive effectors for adoptive immunotherapy of cancer. Results from first-in-human studies using chimeric antigen receptor (CAR)-engineered primary NK cells and NK-92 cells are encouraging in terms of efficacy and safety. In order to further improve treatment strate...

Description complète

Détails bibliographiques
Auteurs principaux:	Nivedha Murali Shankar, Paola Ortiz-Montero, Anastasia Kurzyukova, Wiebke Rackwitz, Stephan R. Künzel, Winfried S. Wels, Torsten Tonn, Franziska Knopf, Jiri Eitler
Format:	Article
Langue:	English
Publié:	Frontiers Media S.A. 2023-10-01
Collection:	Frontiers in Immunology
Sujets:	CAR-NK cells zebrafish xenograft cancer immunotherapy NK-92 PD-L1 ErbB2 (HER2)
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1254821/full

Documents similaires

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
par: Congcong Zhang, et autres
Publié: (2017-05-01)

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
par: Torsten Tonn, et autres
Publié: (2024-02-01)

442-Q CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
par: Torsten Tonn, et autres
Publié: (2023-11-01)

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells
par: Anne Kiefer, et autres
Publié: (2024-01-01)

Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
par: Renata Nacasaki Silvestre, et autres
Publié: (2023-09-01)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
par: Torsten Tonn, et autres
Publié: (2021-01-01)

Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies
par: Jordi Pfeifer Serrahima, et autres
Publié: (2024-08-01)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
par: Catrin Heim, et autres
Publié: (2023-08-01)

In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
par: Amanda G. Tomalka, et autres
Publié: (2018-11-01)

Rational Design of Constrained Peptides as Protein Interface Inhibitors
par: Ramachandran Murali, et autres
Publié: (2021-08-01)

Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer
par: Juheon Lee, et autres
Publié: (2025-01-01)

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
par: Kellsye P. Fabian, et autres
Publié: (2021-12-01)

The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
par: Bara A. Shraim, et autres
Publié: (2021-08-01)

The Signaling of Neuregulin-Epidermal Growth Factor Receptors and Its Impact on the Nervous System
par: Marzia Tagliaferro, et autres
Publié: (2023-10-01)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
par: Xiaopeng Tian, et autres
Publié: (2023-04-01)

Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model
par: Jusuf Imeri, et autres
Publié: (2024-01-01)

Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing
par: Lia Walcher, et autres
Publié: (2021-06-01)

Advantages and Applications of CAR-Expressing Natural Killer Cells
par: Wolfgang eGlienke, et autres
Publié: (2015-02-01)

Three-Dimensional Model Analysis Revealed Differential Cytotoxic Effects of the NK-92 Cell Line and Primary NK Cells on Breast and Ovarian Carcinoma Cell Lines Mediated by Variations in Receptor–Ligand Interactions and Soluble Factor Profiles
par: Nadezhda A. Alekseeva, et autres
Publié: (2024-10-01)

ErbB polymorphisms: Insights and implications for response to targeted cancer therapeutics
par: Moulay A Alaoui-Jamali, et autres
Publié: (2015-02-01)

A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo
par: Zheng Yan, et autres
Publié: (2021-10-01)

ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain
par: Rory Mitchell, et autres
Publié: (2020-08-01)

Reduction of Ca<sup>2+</sup> Entry by a Specific Block of KCa3.1 Channels Optimizes Cytotoxic Activity of NK Cells against T-ALL Jurkat Cells
par: Miguel Olivas-Aguirre, et autres
Publié: (2023-08-01)

Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy
par: Lydia Navarrete-Galvan, et autres
Publié: (2022-04-01)

Characterization of Surface Receptor Expression and Cytotoxicity of Human NK Cells and NK Cell Subsets in Overweight and Obese Humans
par: Wiebke Naujoks, et autres
Publié: (2020-09-01)

Correlative Fluorescence- and Electron Microscopy of Whole Breast Cancer Cells Reveals Different Distribution of ErbB2 Dependent on Underlying Actin
par: Indra Navina Dahmke, et autres
Publié: (2020-06-01)

High-Fat Diet and Feeding Regime Impairs Number, Phenotype, and Cytotoxicity of Natural Killer Cells in C57BL/6 Mice
par: Julia Spielmann, et autres
Publié: (2020-11-01)

EVALUATION OF MICROVESICLES FORMED BY NATURAL KILLER (NK) CELLS USING FLOW CYTOMETRY
par: V. A. Mikhailova, et autres
Publié: (2018-03-01)

Expression and function of Neuregulin 1 and its signaling system ERBB2/3 in the enteric nervous system
par: Martina eBarrenschee, et autres
Publié: (2015-09-01)

Melatonin upregulates ErbB1 and ErbB4, two primary implantation receptors, in pre-implantation mouse embryos
par: Ghazaleh Moshkdanian, et autres
Publié: (2017-06-01)

KTeXpand – a novel microfluidic device for advanced cell based cross matching
par: Schneider Daniel, et autres
Publié: (2022-09-01)

Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements
par: Matyas Meggyes, et autres
Publié: (2021-07-01)

Matrine inhibits the growth of natural killer/T-cell lymphoma cells by modulating CaMKIIγ-c-Myc signaling pathway
par: Jianyou Gu, et autres
Publié: (2020-07-01)

ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation
par: Michelle M. Williams, et autres
Publié: (2017-09-01)

Biotecnología para el estudio de enfermedades neuropsiquiátricas y la búsqueda de nuevos tratamientos: caso de las neuregulinas
par: María Clara Soto-Bernardini
Publié: (2019-09-01)

Statins reduce melanoma development and metastasis through MICA overexpression
par: Christine ePich, et autres
Publié: (2013-03-01)

Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol
par: Ulrike eKoehl, et autres
Publié: (2013-05-01)

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
par: M.I. Strecker, et autres
Publié: (2022-12-01)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
par: Michael Merker, et autres
Publié: (2020-10-01)

Intravenous immunoglobulins and recombinant granulocyte-colony stimulating factor modulate expression of NK cytotoxic receptors
par: A. A. Davydova, et autres
Publié: (2024-11-01)